May 18, 2023
Via: Contract PharmaRevvity, a provider of health sciences services, entered a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile. The Pin-point system and the underlying […]
May 9, 2023
Via: Contract PharmaGilead Sciences, Inc. has acquired all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition adds clinical development pipeline assets for well-validated targets in oncology and inflammation. Through the acquisition, Gilead gains rights to a […]
May 5, 2023
Via: Contract PharmaModerna, Inc., a provider of messenger RNA (mRNA) therapeutics and vaccines, entered into a long-term agreement with Ontario-based Novocol Pharma, a sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines […]
May 1, 2023
Via: Biopharma DiveJapanese drugmaker Astellas Pharma on Sunday agreed to acquire Iveric Bio for about $5.9 billion, betting that a medicine the biotechnology company has developed for a common type of vision loss can help it build an eye drug business. Astellas […]
April 28, 2023
Via: Biopharm InternationalAdaptive Biotechnologies Corporation announced on April 12, 2023 that it has begun a translational collaboration with Takeda. Adaptive Biotechnologies will use its clonoSEQ Assay to assess minimal residue disease (MRD) to start with the development and commercialization of Takeda’s pipeline […]
April 18, 2023
Via: Biopharm InternationalMerck and Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, announced an acquisition agreement on April 16, 2023. Merck will acquire all outstanding shares of the company for $200 per share, a total approximate equity valuation of approximately […]
April 3, 2023
Via: Biopharma DiveArmed with cash earned from sales of the COVID-19 vaccine it developed with Pfizer, BioNTech has been investing in cancer drug research and development — its primary focus prior to the pandemic. While BioNTech specializes in messenger RNA, it also […]
March 31, 2023
Via: Biopharma DiveSartorius, a Germany-based manufacturer and supplier to the biopharmaceutical industry, is acquiring France’s Polyplus in a $2.6 billion acquisition meant to expand the company’s role as partner to gene and cell therapy developers. Under a deal announced Friday, Sartorius will […]
March 30, 2023
Via: Contract PharmaJunshi Biosciences Co., Ltd and Rxilient Biotech entered into a collaboration for the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab, through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the […]
Cell and Gene Therapy, Industry, Mergers and Acquisitions
March 28, 2023
Via: Biopharma DiveRegeneron became one of biotech’s most valuable companies through its success making antibody drugs. Its flagship technology, a way of testing potential medicines on genetically modified mice, has helped it unearth antibody treatments for eye diseases, autoimmune conditions, rare disorders […]
March 24, 2023
Via: Biopharm InternationalCuria announced on March 23, 2023 that it is collaborating with Corning to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally. The collaboration marks the first global installation of Corning’s G1 production system […]
March 24, 2023
Via: Contract PharmaHarm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths, signed a commercial supply agreement with Catalent for the manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive (3.0 mg), for the emergency treatment of […]
Clinical Trials, Mergers and Acquisitions, Research and Development
March 10, 2023
Via: Contract PharmaLEO Pharma, a global leader in medical dermatology, and ICON plc, entered into a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, to support the company’s clinical portfolio. The partnership […]
Industry, Mergers and Acquisitions, Vaccines
March 9, 2023
Via: PMLiVEThe partnership will see both companies advance MDX-2201 to an Investigational New Drug application filing, after which Merck will be responsible for clinical and regulatory activities, as well as product commercialisation. In exchange, Opko will receive an upfront payment of […]
March 6, 2023
Via: Biopharma DiveThe deal highlights the funding difficulties that development-stage biotechnology companies continue to face amid a sector-wide downturn that has weakened investor interest. This has led to a spate of layoffs and consolidation across the industry. Before the companies’ respective layoffs […]
February 24, 2023
Via: Biopharma DiveRoche is terminating its collaboration with biotechnology company Blueprint Medicine and handing back commercial rights to its lung cancer treatment Gavreto. The move comes weeks after the Swiss drugmaker took impairment charges worth 663 million Swiss francs, or about $706 […]
February 17, 2023
Via: Contract PharmaLIfT BioSciences, a pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil progenitor based cell therapy, and Minaris Regenerative Medicine GmbH, a global contract development and manufacturing organization (CDMO) provider for the cell and gene therapy industry, have […]
Cell and Gene Therapy, Industry, Mergers and Acquisitions
February 16, 2023
Via: Contract PharmaCharles River Laboratories International, and Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration. Supporting the first gene therapy platform targeting renal diseases, that […]
February 16, 2023
Via: PMLiVEThe companies will still continue to work together on their SARS-CoV-2-targeting antibody, sotrovimab, in markets where it is authorised, as well as their experimental COVID-19 antibody, VIR-7832, and a portfolio of other therapies for respiratory diseases such as influenza. Originally […]
February 15, 2023
Via: Biopharm InternationalGenScript ProBio, a US-based contract development and manufacturing organization specializing in biologics, and Bio Immunitas, a UK-based pharmaceutical company, announced a joint collaboration on Feb. 8, 2023. The aim of this partnership is to develop and fast track manufacturing of […]